Sign In
Buy ANIX
$2.52
-0.0300 (-1.18%)
At Close: Jun 03, 2026
Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
08:30am, Monday, 10'th Mar 2025
SAN JOSE, Calif. , March 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today an
SAN JOSE, Calif. , March 3, 2025 /PRNewswire/ -- Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announce
Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial
08:00am, Wednesday, 26'th Feb 2025
SAN JOSE, Calif. , Feb. 26, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann
Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"
07:30am, Tuesday, 25'th Feb 2025
SAN JOSE, Calif. , Feb. 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann
Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer
08:00am, Monday, 24'th Feb 2025
SAN JOSE, Calif. , Feb. 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today is
Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial
08:00am, Tuesday, 18'th Feb 2025
Amendment expands the potential benefits of CAR-T therapy allowing a second dose and includes more ovarian cancer histologies SAN JOSE, Calif. , Feb. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc.
SAN JOSE, Calif. , Feb. 14, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann
Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum
08:30am, Tuesday, 11'th Feb 2025
SAN JOSE, Calif. , Feb. 11, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today an
Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention
08:30am, Tuesday, 04'th Feb 2025
SAN JOSE, Calif. , Feb. 4, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today anno
Anixa Biosciences CEO Provides Letter to Shareholders
08:30am, Tuesday, 21'st Jan 2025
SAN JOSE, Calif. , Jan. 21, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today pro
Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10
08:30am, Wednesday, 04'th Dec 2024
SAN JOSE, Calif , Dec. 4, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, announced
Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
08:15am, Friday, 22'nd Nov 2024
SAN JOSE, Calif. , Nov. 22, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
08:20am, Monday, 18'th Nov 2024
Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose SAN JOSE, Calif. , Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NA
Data continues positive trend as additional patients are enrolled in 3 cohorts Vaccine was safe and well tolerated by participants in all 3 cohorts Protocol defined immune responses were exhibited in
SAN JOSE, Calif. , Nov. 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today anno
